ACLARIS THERAPEUTICS INC
- Country
- 🇮🇳India
- Ownership
- Public
- Established
- 2009-01-01
- Employees
- 101
- Market Cap
- $84.9M
- Website
- http://www.aclaristx.com
Safety and Pharmacokinetic Study of ATI-50002 in Subjects With Alopecia Universalis (AU) and Alopecia Totalis (AT)
- Conditions
- Interventions
- First Posted Date
- 2017-10-20
- Last Posted Date
- 2020-07-02
- Lead Sponsor
- Aclaris Therapeutics, Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT03315689
- Locations
- 🇺🇸
Aclaris Investigational Site, New York, New York, United States
A Study of A-101 Topical Solution Administered Twice a Week in Subjects With Common Warts
- Conditions
- Interventions
- First Posted Date
- 2017-09-11
- Last Posted Date
- 2019-04-09
- Lead Sponsor
- Aclaris Therapeutics, Inc.
- Target Recruit Count
- 159
- Registration Number
- NCT03278028
- Locations
- 🇺🇸
Aclaris Investigational Site, Norfolk, Virginia, United States
A Study of A-101 Topical Solution in Subjects With Dermatosis Papulosa Nigra
- First Posted Date
- 2017-07-21
- Last Posted Date
- 2020-03-30
- Lead Sponsor
- Aclaris Therapeutics, Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT03224598
- Locations
- 🇺🇸
Aclaris Investigational Site, New York, New York, United States
A Phase2 of A-101 Topical Solution in Subjects With Common Warts
- Conditions
- Interventions
- First Posted Date
- 2017-07-06
- Last Posted Date
- 2019-05-01
- Lead Sponsor
- Aclaris Therapeutics, Inc.
- Target Recruit Count
- 157
- Registration Number
- NCT03210337
- Locations
- 🇺🇸
Aclaris Investigational Site, San Antonio, Texas, United States
A Randomized, Vehicle-Controlled Study of 2 Concentrations of A-101 for the Treatment of Seborrheic Keratosis
- First Posted Date
- 2017-05-11
- Last Posted Date
- 2019-05-06
- Lead Sponsor
- Aclaris Therapeutics, Inc.
- Target Recruit Count
- 253
- Registration Number
- NCT03148691
- Locations
- 🇺🇸
Philadelphia Institute - Dermatology, Fort Washington, Pennsylvania, United States
🇺🇸The Skin Wellness Center, PC Clinical Research Division, Knoxville, Tennessee, United States
🇺🇸Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania, United States
A Study of A-101 Solution in Subjects With Common Warts.
- Conditions
- Interventions
- First Posted Date
- 2016-02-01
- Last Posted Date
- 2018-12-07
- Lead Sponsor
- Aclaris Therapeutics, Inc.
- Target Recruit Count
- 98
- Registration Number
- NCT02669862
- Locations
- 🇺🇸
Aclaris Therapeutics, Inc., Wayne, Pennsylvania, United States
An Open-Label Safety Study of A-101 Solution
- First Posted Date
- 2016-01-28
- Last Posted Date
- 2018-02-07
- Lead Sponsor
- Aclaris Therapeutics, Inc.
- Target Recruit Count
- 147
- Registration Number
- NCT02667288
- Locations
- 🇺🇸
Aclaris Therapeutics, Inc., Malvern, Pennsylvania, United States
A Study of A-101 Solution 40% in Subjects With Seborrheic Keratosis.
- Conditions
- Interventions
- First Posted Date
- 2016-01-28
- Last Posted Date
- 2018-02-06
- Lead Sponsor
- Aclaris Therapeutics, Inc.
- Target Recruit Count
- 450
- Registration Number
- NCT02667236
- Locations
- 🇺🇸
Aclaris Therapeutics, Inc., Malvern, Pennsylvania, United States
A Randomized, Double-Blind, Vehicle-Controlled Study in Subjects With Seborrheic Keratosis
- Conditions
- Interventions
- First Posted Date
- 2016-01-28
- Last Posted Date
- 2018-02-06
- Lead Sponsor
- Aclaris Therapeutics, Inc.
- Target Recruit Count
- 487
- Registration Number
- NCT02667275
- Locations
- 🇺🇸
Aclaris Therapeutics, Inc., Malvern, Pennsylvania, United States
Study of A-101 for the Treatment of Seborrheic Keratosis
- First Posted Date
- 2014-10-09
- Last Posted Date
- 2020-12-02
- Lead Sponsor
- Aclaris Therapeutics, Inc.
- Target Recruit Count
- 119
- Registration Number
- NCT02260180
- Locations
- 🇺🇸
Oregon Medical Research Center, Portland, Oregon, United States
🇺🇸Philadelphia Institute of Dermatology, Fort Washington, Pennsylvania, United States
🇺🇸DermReseach, Inc., Austin, Texas, United States